HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.

Altre lingue Harvard Apparatus Regenerative Technology Inc.

Azioni

HRGN

US09074M2026

Mercato chiuso - OTC Markets Altri mercati azionari 15:30:07 17/04/2024			Variaz. 5gg	Var. 1 gen.
2,65 ^USD	-0,75%		-0,38%	-46,89%

28/03	Harvard Apparatus Regenerative Technology Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
2023	Harvard Apparatus Regenerative Technology Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Harvard Apparatus Regenerative Technology : March 19, 2024 - Investor Presentation	18/03
Harvard Apparatus Regenerative Technology : Q4 - 2023 HBIO Quarterly Earnings Presentation	07/03
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Harvard Apparatus Regenerative Technology : Northland Capital Markets Institutional Investor Conference 2023	18/09/23
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Harvard Apparatus Regenerative Technology : Q2 - 2023 HBIO Quarterly Earnings Presentation	08/08/23
Biostage Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	19/07/23
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	18/07/23
Purcell & Lefkowitz LLP Is Investigating Biostage, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors	15/06/23
Biostage to Host Investor Call	13/06/23
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
Biostage, Inc. announced that it has received $6.005802 million in funding	13/04/23
BIOSTAGE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	10/04/23
Biostage Appoints Ron Packard to Board of Directors	10/04/23
Biostage, Inc. Appoints Ron Packard to Board of Directors	10/04/23
BIOSTAGE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)	06/04/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Harvard Apparatus Regenerative Technology Inc.

Azioni

HRGN

US09074M2026

Altre lingue

Filtri